Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Treatment of anaemia with human recombinant erythropoietin (r-Hu EPO) substantially improves the quality of life of patients receiving regular dialysis treatment. The positive effect on the nutritional state of patients during r-Hu EPO treatment is not accepted unequivocally so far. The authors followed-up 9 patients (6 men and 3 women) who had regular dialysis treatment, and suffered from severe anaemia. The patients were treated for 12 months with r-Hu EPO (preparation Eprex Cilagd Co.) with an initial dose of 30 mu/kg 3x per week by s.c. route with a target haemoglobin (Hb) value of 90-100 g/l. Before treatment during the 6th and 12th month of treatment the basic nutritional parameters of the patients were followed up. In the course of the investigation the Hb level (x +/- SD) increased from 61 +/- 12 g/l to 98 +/- 8 g/l, p < 0.01. On comparison of the nutritional parameters before treatment and after 12 months of treatment with r-Hu EPO the authors recorded rising trends in the patients' body weight (kg) from 67.4 +/- 12.2 to 68.4 +/- 11.2 (n.s.), an increase of the skinfold thickness above the triceps brachii muscle (mm) from 8.6 +/- 5.8 to 9.8 +/- 4.3 (n.s.), a decline of skin reactivity to diphtheric antigen (mm) from 2.1 +/- 2.8 to 1.8 +/- 0.8 (n.s.), a rising trend of reactivity to Candida antigen (mm) from 2.9 +/- 2.2 to 3.9 +/- 2.4 (n.s.), to diphtheric antigen from 3.0 +/- 3.3 to 5.1 +/- 3.8 (n.s.), a rise of the transferrin level (g/l) from 2.5 +/- 0.3 to 2.8 +/- 1.3 (n.s.), a rise of serum urea (mmol/l) from 25.7 +/- 3.6 to 32.5 +/- 9.5 (n.s.), a rise of Mullen's nutritional index from 21.8 +/- 15.5 to 22.3 +/- 24.7 (n.s.).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Evaluation of the nutritional status during treatment of anemia using erythropoietin in patients on regular dialysis therapy]. 807 61

The possibility of serious complications of infection and GVHD and adverse prognosis in cancer patients resulting from homologous blood transfusions has been reported. We used recombinant human erythropoietin (rHuEPO) in autologous blood transfusions for radical hysterectomies to avoid the risks associated with transfusions. rHuEPO efficacy, stability and influence on hemodynamics were investigated. All patients were able to donate 1,200 ml of autologous blood prior to surgery, and anemia did not result despite phlebotomy three times each week. Elevation in Hb concentration was calculated at 0.78 +/- 0.37 g/dl over the first 7 days, and 2.12 +/- 0.35 g/dl over the first 14 days. No adverse side effects were observed in any patient. The serum EPO level was measured by RIA, and compared to the homologous blood transfusion group. rHuEPO did not influence postoperative EPO secretion. Autologous blood transfusion with rHuEPO in radical hysterectomy was extremely effective in mitigating the risks associated with homologous blood transfusions.
 ...
PMID:Autologous blood transfusion using recombinant human erythropoietin in radical hysterectomy. 809 59

In a two-way study, we treated renal anemia in chronic hemodialysis patients with recombinant human erythropoietin (rh-EPO) and followed heart morphology and function dynamics by echocardiography. Thirty-eight patients were randomly divided in two equal groups: the therapy group, treated with rh-EPO for 24 months, and the control group, not treated during the first 12 months and treated with rh-EPO during the second 12 months. Anemia was corrected, and hematocrit was maintained between 30 and 35 vol% by subcutaneous rh-EPO administration. Echocardiographic assessment was performed at the end of the untreated control phase and was repeated after 12 months of rh-EPO treatment in the control group and after 12 and 24 months of treatment in the therapy group. The results revealed significant morphologic, hemodynamic, and eventually functional changes. After 12 months of rh-EPO treatment, the end-diastolic volume (EDV) decreased from 135.8 +/- 23.7 to 109.8 +/- 25.3 ml, p < 0.001; stroke volume (SV) from 91.9 +/- 17.6 to 71.3 +/- 12.4 ml, p < 0.001; left ventricular mass-Devereux (LVMD) from 297.2 +/- 57.8 to 218.0 +/- 50.4 g, p < 0.01; cardiac output (CO) from 7,279 +/- 1,932 to 5,711 +/- 1,276 ml/min, p < 0.002; total peripheral resistance (TPR) rose from 1,330 +/- 390 to 1,707 +/- 373 dynes x s/cm5, p < 0.007. After 24 months, LVMD decreased further from 224.6 +/- 43.1 to 195.7 +/- 46.3 g, p < 0.004. The relaxation time index (RTI) decreased from 64.7 +/- 20.4 to 52.4 +/- 18.0 ms, p < 0.045, suggesting improved diastolic function.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. 811 72

Eleven children aged 0.6-17 years with preterminal chronic renal failure and anemia (mean serum creatinine concentration 4.8 mg/dl; mean hemoglobin concentration 7.9 g/dl) were treated with sc injections of recombinant human erythropoietin (EPO, initial dose 150 U/kg/week) over a mean period of 13 months. When a target hemoglobin concentration of 11.5-13.5 g/dl was reached, the dose was adapted. Iron deficiency was corrected. Hemoglobin concentration increased by > 2 g/dl in all patients within 14-119 (mean 45) days. The last maintenance dose ranged between 75 and 300 (mean 133) U/kg/week. No major adverse effects were observed, except for hypertension which occurred in about half of the patients and necessitated interruption of EPO in one child with advanced renal failure. Additional antihypertensive drugs were given to five patients. Body height increased in two patients by 0.6 and 1.3 SDS/year, respectively. In six patients with a mean observation period of 14 months before and 16 months after the start of EPO, the mean slope of the reciprocal serum creatinine concentration curve improved slightly (p = 0.05). The proposed schedule appears to be safe for the treatment of renal anemia in most pre-dialysis patients. Frequent monitoring of hemoglobin, blood pressure, serum creatinine and ferritin is required.
 ...
PMID:Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. 811 Nov 77

Patients with relatively higher endogenous EPO levels (> 100 U/L) in the Arkansas study showed late responses or failed to respond, analogous to earlier observations by Ludwig et al, as well as by Fischl et al, and colleagues, who studied r-HuEPO administration in acquired immunodeficiency syndrome patients receiving r-HuEPO for anemia associated with zidovudine therapy. Thus, r-HuEPO substitution therapy is more likely to benefit patients whose anemia is associated with inappropriately low EPO serum levels. Granulopoiesis and thrombopoiesis were unaffected, and multiple myeloma cell stimulation has not been observed. The relative lack of toxicity from subcutaneously administered r-HuEPO at a dose of 150 U/kg three times weekly makes this approach an effective adjunct in the management of patients with multiple myeloma, especially those unresponsive to chemotherapy and remaining symptomatic from their anemia.
 ...
PMID:Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin. 815 75

Serum erythropoietin (Epo) concentrations were measured by radioimmunoassay (RIA) in normal, polycythemic, and anemic dogs and cats. The serum Epo concentration in normal dogs (n = 25) ranged from 7 to 37 mU/mL (median, 20 mU/mL); and in normal cats (n = 11) ranged from 9 to 38 mU/mL (median, 18 mU/mL). Polycythemic animals (PCV > 55% in dogs, > 45% in cats) were classified as those with primary (polycythemia vera), secondary, or polycythemia of uncertain etiology. Dogs with polycythemia vera (PV, n = 8) had a median serum Epo concentration in the normal range (17 mU/mL); cats with PV (n = 7) also had a median serum Epo concentration that was within the normal range (10 mU/mL). In the category of secondary polycythemias, dogs (n = 7) (median, 30.7 mU/mL) and cats (n = 2) had normal Epo concentrations. The median serum Epo concentration was significantly decreased (P < .05) in dogs with PV compared with dogs with secondary polycythemias. The median serum Epo concentrations in dogs (n = 13) and cats (n = 5) with anemias not due to chronic renal disease were significantly increased (P < .05) compared with normal dogs and cats. In cats with anemias due to chronic renal disease (n = 5) the median serum Epo concentration was not significantly different from normal cats. The measurement of the serum EPO concentration may be useful in assessment of anemia or polycythemia but the overlap of values with the normal range in all groups evaluated limit its diagnostic use.
 ...
PMID:Serum erythropoietin concentrations measured by radioimmunoassay in normal, polycythemic, and anemic dogs and cats. 784 80

In patients with the anemia of chronic diseases, the plasma level of EPO is often low in relation to the blood hemoglobin concentration. Because infectious and inflammatory processes cause activation of cytokine-producing macrophages and lymphocytes, we investigated whether isolated inflammatory cytokines influence the synthesis of EPO in vitro. IL-1 and TNF-alpha were shown to inhibit EPO mRNA levels and EPO formation in the human hepatoma cell cultures HepG2 and Hep3B, and to lower EPO formation in isolated perfused rat kidneys. IFN-alpha and IFN-beta also induced some inhibition of EPO production in HepG2 cultures. IL-3, TGF-beta 2, and IFN-gamma did not inhibit. IL-6 stimulated the production of EPO in Hep3B cells but was ineffective in HepG2 cells and lowered EPO production in isolated perfused rat kidneys. IL-1, TNF-alpha, and possibly other cytokines could contribute to defective EPO production in renal and nonrenal immune responses.
 ...
PMID:Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. 818 37

Since recombinant human erythropoietin (r-Hu EPO) has been introduced to the treatment of anemia in uremic patients the issue of optimal therapy appeared. For proper erythropoiesis not only erythropoietin but also iron, folic acid and B12 vitamin are needed. Iron deficiency is one of the most common factors causing resistance to r-Hu EPO in uremic patients, so its recognition and eventual supplementation is required for optimal hemopoietic response. The aim of presented study, besides monitoring hematological changes, was to measure iron status parameters such as iron, transferrin, ferritin and percentage of hypochromic erythrocytes and estimation of their usefulness in monitoring iron deficiency during r-Hu EPO treatment.
 ...
PMID:Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients. 819 28

Recombinant human erythropoietin (r-Hu EPO) has proved to be effective in correcting anemia of dialyzed patients. Since 1987 reports have been published announcing the introduction of this hormone to the treatment of anemia in pre-dialyzed patients, too. Besides successful correction of anemia no evidence of acceleration of the progression of renal failure has been noted. The question of whether r-Hu EPO can also correct metabolic disturbances in predialyzed patients is to be answered. These metabolic disturbances comprises, among others, the decrease in thiamine content in blood and the deterioration of erythrocytes transketolase activity (ETKA) we described in another paper. However, as to the present we did not notice any publication concerning the impact, of r-Hu EPO administration on thiamine content in blood and on the ETKA. The purpose of our study was therefore to determine the influence of r-Hu EPO therapy in pre-dialyzed patients on thiamine level in plasma and erythrocytes and on the ETKA. Additionally, we wanted to answer the question if there was any parallel change in hematocrit index, thiamine level in blood and the ETKA in patients we observed during r-Hu EPO therapy.
 ...
PMID:Recombinant human erythropoietin administration improves thiamine content in blood and erythrocytes transketolase activity in pre-dialyzed patients. 819 30

The dialysis adequacy was considered as the treatment method which eradicated the symptoms and signs of uremia and led to the full rehabilitation of treated patients. The chronic renal failure patients substitutional treatment using both peritoneal dialysis and hemodialysis assures correction of biochemical disturbances but only 33% of dialyzed patients are fully rehabilitated. Such situation is caused by the uremic anemia. The erythropoietin deficit is the main reason of the uremic anemia. The clinical effects of the erythropoietin treatment in hemodialyzed, peritoneal dialyzed and pre-dialyzed patients were proved. The erythrocytes increment to the normal or almost normal levels may caused the dialysis kinetics changes. During the r-Hu EPO treatment in both hemodialyzed and peritoneal dialyzed patients the dialysis effectiveness changes occurred. The dialysis therapy adequacy is mainly caused by the dialysis efficiency and additionally by the residual renal function and metabolism state. Taking into account own peritoneal dialysis kinetics parameters research results during the r-Hu EPO treatment the dialysis adequacy was evaluated. The aim of this study was the optimal dialysis scheme definition when the peritoneal transfer changes occurred as the r-Hu EPO treatment effect.
 ...
PMID:Peritoneal dialysis adequacy during the r-Hu EPO treatment. 819 32


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>